combination with the cation-exchange high-performance liquid chromatography (CE-HPLC) Bio-Rad Variant II™ instrument β-thalassemia Short Program (Bio-Rad Laboratories, Munich, Germany). Specifically in case of suspicion of HbS, a sickle solubility test instead of CE-HPLC is used to confirm its presence. This approach is important for initial diagnosis, requires experience, and is quite laborious. Although sickle solubility tests have a good specificity, their sensitivity is quite low and yield qualitative results. Routine hemoglobinopathy screening is performed twice a week in batch by a select group of trained laboratory technicians. Therefore, in case of urgent RCE a 24/7 short turnaround time (STAT) analysis, with the ability to identify and quantify pre-and post-transfusion HbS, is mandatory. RCE is monitored by a decrease in HbS (HbS level, <30%), in combination with the Hb level (close to but not >10 g dL -1 ). 4, 5 We evaluated the analytical performance of Tosoh Automated Glycohemoglobin Analyzer HLC-723G8
(TOSOH G8) (Tosoh Europe, Amsterdam, the Netherlands) for this purpose, using the variant HbA1c mode. Results were compared with our routine analyzer Minicap FP system to evaluate analytical and clinical concordance.
| MATERIAL S AND ME THODS

| Patient sample selection and storage
The study was performed with full respect for individuals' rights to confidentiality and in accordance with procedures supervised by local authorities responsible for ethical research. The study was conducted with sample leftovers from routine hemoglobinopathy screening. All samples were aliquoted and stored at −80°C until analyses. The used anticoagulant was ethylenediaminetetraacetic acid (EDTA). mode is not the dedicated mode for hemoglobinopathy screening.
| High-performance liquid chromatography
The instrument is equipped to lyse whole blood samples collected in EDTA tubes and to separate the different Hb fractions. The separation is obtained by CE-HPLC using 3 positively charged buffers.
Hb is separated into 6 different fractions: A1A, A1B, F, LA1C+, SA1C, and A0. In addition, the major Hb variants hemoglobin D (HbD), HbS, and hemoglobin C (HbC) can be identified. HbS is reported as H-V1.
Detection of the separated Hb fractions and Hb variants is accomplished by measuring the absorbance at a wavelength of 415 nm. Time of analysis is 1.6 minutes per sample (no centrifugation).
| Capillary zone electrophoresis
Capillary zone electrophoresis (CZE) was performed using Minicap FP system-HEMOGLOBIN(E) according to the manufacturer's instructions. The instrument is equipped to suspend and lyse whole blood samples collected in EDTA tubes and to separate Hb variants. was analyzed in duplicate on TOSOH G8 in variant HbA1c mode.
In addition, to confirm the linearity in the low HbS range, a second linearity study was performed (0% to 19%) also using duplicate measurements of a dilution set of 11 samples. Expected HbS percentages of the dilution sets were calculated, taking into account the Hb concentration in the undiluted samples.
| Method comparison
After thawing and vortexing, a selection of samples from patients with sickle cell trait (n = 5) and patients with sickle cell anemia (n = 27) were analyzed both on TOSOH G8 and Minicap FP system on the same day. HbS concentration ranged from 9% to 93%
and hemoglobin F (HbF) concentration ranged from 0% to 50% on Minicap FP system.
| Statistics
To investigate linearity, the measured and expected fractions were compared using linear regression. An acceptable linearity
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| RE SULTS
| Analytical performance of TOSOH G8 in variant HbA1c mode
Following Clinical and Laboratory Standards Institute guidelines EP5-a, the within-run, between-run and total coefficients of variation (CVs) of HbS analysis were estimated for 1 sickle cell trait sample and 1 sickle cell anemia sample. Within-run, between-run and total CV were <2% as proposed by Stephens et al 6 ( Table 2) .
During the linearity study in the low HbS range, TOSOH G8 could not detect HbS in the 2 samples with the highest dilution factor and expected HbS concentrations of 3.84% and 1.92%. Those samples were excluded and an acceptable linearity was observed (HbS range, 6%-19%, R 2 = .997 [ Figure 1A] ). In addition, an acceptable linearity between 8% and 88% HbS was observed (R 2 = .998) in the second linearity study ( Figure 1B ).
| Method comparison
Passing-Bablok regression analysis comparing HbS results ob- Figure 3B ). Chromatograms obtained with each system for an HbSS sample are shown in Figure 4 .
| D ISCUSS I ON
The aim of this study was to investigate the suitability of TOSOH G8
in variant HbA1c mode to identify and quantify HbS as a 24/7 STAT 
Analytical performance of variant Hb quantification on TOSOH G8
in the variant HbA1c mode was not assessed. Quantitative data from our study were generated using leftover samples from patients with sickle cell trait and sickle cell anemia.
Our study showed a good analytical performance for HbS quantification using TOSOH G8 in variant HbA1c mode, as evidenced by the low within-run, between-run and total CV and the acceptable linearity (HbS range, 6%-88%).
In the clinical laboratory of the University Hospitals Leuven, a sickle solubility test is used to confirm HbS when an Hb variant with the electrophoretic characteristics of HbS is detected on CZE. The sickle solubility test can be performed using the necessary in-house reagents or a commercial kit. Sickle solubility test can generate falsepositive results (eg, increased plasma proteins or large amounts of Heinz bodies) and false-negative results when the proportion of HbS is <20% (eg, early neonatal period). Therefore, we were interested in the linearity of the HbS analysis on TOSOH G8 in variant HbA1c mode in the low HbS range (HbS range: 0%-19%). During the linearity study, it was noticed that TOSOH G8 in variant HbA1c mode could not detect HbS in 2 samples with an expected HbS concentration of 3.84% and 1.92%. However, the expected HbS concentration of 5.66% was correctly detected and quantified on TOSOH G8. In addition, this sample was analyzed 10 times on TOSOH G8 (mean value:
5.87% HbS) and an acceptable CV (1.64%) was obtained. Based on these findings, the detection limit of HbS analysis on TOSOH G8
in variant HbA1c mode can be assumed to be approximately 6%.
Therefore, HbS analysis on TOSOH G8 in variant HbA1c mode can replace the sickle solubility test during routine hemoglobinopathy screening. The sickle solubility test can still be used to confirm the positive results on TOSOH G8 in variant HbA1c mode.
F I G U R E 1 Linearity study hemoglobin S (HbS) measurement on TOSOH G8: A, HbS range, 6%-19%; B, HbS range, 8%-88%
F I G U R E 2 Passing-Bablok regression analysis comparing hemoglobin S (HbS) results (A) and hemoglobin F (HbF) results (B) obtained with TOSOH G8 in variant HbA1c mode and Minicap Flex Piercing (FP) system
Good correlation with Minicap FP system was found for both performed by using CZE Minicap FP in combination with CE-HPLC Variant II™.
In conclusion, HbS quantification on TOSOH G8 in variant
HbA1c mode is suitable to monitor urgent RCE. The observed underestimation will not alter clinical decision-making. In addition, our study shows the possibility to replace the sickle solubility test as a screening tool to detect HbS using HbS measurements on TOSOH 
